

Board of Directors:	Ognian Donev, PhD Vessela Stoeva Alexander Todorov - up to 29.06.2011 Alexander Chaushev - from 29.06.2011 Unipharm AD represented by Ognian Palaveev Andrey Breshkov
Executive Director:	Ognian Donev, PhD
Finance Director:	Boris Borisov
Chief Accountant:	Yordanka Petkova
Head of Legal Department:	Galina Angelova
Address of Management:	Sofia 16, Iliensko Shousse Str.
Lawyers:	Adriana Baleva Venelin Gachev Ventsislav Stoev Lyubimka Georgieva Stefan Yovkov
Servicing Banks:	Raiffeisenbank (Bulgaria) EAD ING Bank DSK Bank EAD Eurobank and EFG Bulgaria AD Piraeus Bank AD UniCredit Bulbank AD BNP Paribas Bulgaria EAD Citibank N.A. MKB Unionbank
Auditors:	AFA OOD

SOPHARMA GROUP**CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME****for the three-month period ended 31 March 2012**

	Attachments	2012 BGN'000	2011 BGN'000 <i>Unaudited, Reviewed under ISRE</i>
Revenue	3	173,167	164,801
Other operating income/(losses), net	4	787	364
Changes in inventories of finished goods and work in progress		1,609	(785)
Expenses on materials	5	(25,166)	(21,314)
Hired services expense	6	(13,235)	(12,601)
Employee benefits expense	7	(16,310)	(15,236)
Depreciation and amortisation expense	14, 15	(4,585)	(4,230)
Carrying amount of goods sold	8	(97,595)	(95,792)
Other operating expenses	9, 10	(1,764)	(1,947)
Profit from operations		16,908	13,260
Finance income	11	1,185	1,512
Finance costs	12	(1,997)	(2,441)
Finance (costs)/income, net		(812)	(929)
Profit/(loss) from net monetary position recalculated under hyper inflation	2.33.4	(2,223)	-
Profit before income tax		13,873	12,331
Income tax expense		(1,747)	(1,472)
Net profit for the period		12,126	10,859
Other comprehensive income:	13		
Net change in fair value of available-for-sale financial assets		-	33
Exchange differences on translating foreign operations		458	96
Other comprehensive income for the period, net of tax		458	129
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		12,584	10,988
Net Profit attributable to:			
Equity holders of the parent		11,333	10,617
Non-controlling interest		793	242
Total comprehensive income attributable to:			
Equity holders of the parent		11,229	10,656
Non-controlling interest		1,355	332

The accompanying notes on pages 5 to 96 form an integral part of the consolidated interim financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Yordanka Petkova

SOPHARMA GROUP**CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION**

as at 31 March 2012

	Attachments	31 march 2012 BGN'000	31 december 2011 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	14	242,278	236,338
Intangible assets	15	28,763	27,979
Investment property	16	6,553	6,555
Available-for-sale investments	17	20,245	19,972
Loans granted to related parties	18	736	729
Deffered tax assets		2,150	1,709
Other non-current assets	19	828	848
		301,553	294,130
Current assets			
Inventories	20	120,174	126,022
Trade receivables	21	148,071	136,756
Receivables from related parties	22	64,388	63,113
Other receivables and prepayments	23	25,888	24,332
Cash and cash equivalents	24	16,094	32,235
		374,615	382,458
TOTAL ASSETS		676,168	676,588
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		132,000	132,000
Reserves		33,397	33,534
Retained earnings		165,774	154,465
		331,171	319,999
Non-controlling interest		46,522	45,813
TOTAL EQUITY	25	377,693	365,812
LIABILITIES			
Non-current liabilities			
Long-term bank loans	26	24,179	23,280
Deferred tax liabilities		7,803	6,531
Retirement benefit obligations	27	2,430	2,389
Finance lease liabilities	28	1,507	1,534
Other non-current liabilities	29	2,967	1,368
		38,886	35,102
Current liabilities			
Short-term loans from banks	30	149,781	151,765
Current portion of long-term bank loans	26	43,401	42,650
Trade payables	31	50,126	66,134
Payables to related parties	32	4,433	3,360
Payables to personnel and for social security	33	5,962	5,487
Tax payables	34	3,138	3,046
Other current liabilities	35	2,748	3,232
		259,589	275,674
TOTAL LIABILITIES		298,475	310,776
TOTAL EQUITY AND LIABILITIES		676,168	676,588

The accompanying notes on pages 5 to 96 form an integral part of the consolidated interim financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Yordanka Petkova

SOPHARMA GROUP
CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
for three-month period ended 31 March 2012

	Attachments	2012 BGN'000	2011 BGN'000 <i>Unaudited, Reviewed under ISRE</i>
Cash flows from operating activities			
Cash receipts from customers		187,595	196,514
Cash paid to suppliers		(163,769)	(144,876)
Cash paid to employees and for social security		(15,195)	(13,422)
Taxes paid (except income taxes)		(10,234)	(10,758)
Taxes refunded (except income taxes)		1,986	2,110
Income taxes paid		(1,784)	(1,969)
Interest and bank charges paid on working capital loans		(2,173)	(2,222)
Foreign currency exchange, net		(360)	(307)
Other proceeds/(payments), net		(725)	(638)
Net cash flows from operating activities		(4,659)	24,432
Cash flows from investing activities			
Purchases of property, plant and equipment		(10,327)	(8,663)
Proceeds from sales of property, plant and equipment		63	47
Purchases of intangible assets		(802)	(25)
Purchases of available-for-sale investments		(199)	(197)
Proceeds from sales of available-for-sale investments		2	544
Consideration paid on acquisition of associates		(143)	(1,414)
Cash received / (paid) on acquisition of subsidiaries, net		(28)	-
(Payments)/proceeds on transactions with non-controlling interest, net		3	(394)
Loans granted to related parties		(2,310)	(31,038)
Loan repayments by related parties		1,932	5,646
Loans granted to third parties		(237)	(1,312)
Loan repayments by third parties		39	706
Interest received on loans granted		394	262
Interest received on investment purpose term deposits		24	27
Net cash flows used in investing activities		(11,589)	(35,811)
Cash flows from financing activities			
Proceeds from short-term bank loans		184,938	22,492
Repayment of short-term bank loans		(186,560)	(24,019)
Proceeds from long-term bank loans		3,345	2,570
Repayment of long-term bank loans		(1,523)	(9,032)
Interest and charges paid under investment purpose loans		(291)	(105)
Payment of finance lease liabilities		(212)	(143)
Purchases of treasury shares		(7)	(1,746)
Proceeds from treasury shares		-	747
Received donations from public companies		1,824	-
Dividends paid		(599)	(500)
Other proceeds/(payments), net		-	2
Net cash flows (used in) / from financing activities		915	(9,734)
Effect from recalculated under hyper inflation		(808)	-
Net (decrease) / increase in cash and cash equivalents		(16,141)	(21,113)
Cash and cash equivalents at 1 January		32,235	45,069
Cash and cash equivalents at 31 March	24	16,094	23,956

The accompanying notes on pages 5 to 96 form an integral part of the consolidated interim financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Yordanka Petkova

SOPHARMA GROUP										
CONSOLIDATED INTERIM STATEMENT OF CHANGES IN OWNERS EQUITY										
for three-month period ended 31 March 2012										
			Attributable to equity holders of the parent						Non-controlling interest	Total owners equity
		Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, pland and equipment	Available-for-sale financial assets reserve	Translation of foreign operations reserve	Retained earnings	Total	
Attachments		BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000
		132,000	(4,643)	17,788	24,267	(354)	(2,427)	131,601	298,232	49,047
										347,279
Balance at 1 January 2011										
Changes in equity for 2011										
Effect of treasury shares acquisition		-	(6,820)	-	-	-	-	75	(6,745)	-
Distribution of profit for:										
* <i>reserves</i>		-	-	4,067	-	-	-	(4,067)	-	-
* <i>dividends</i>		-	-	-	-	-	-	(11,081)	(11,081)	-
Effects assumed by non-controlling interest on:		-	-	-	-	-	-	(573)	(573)	(5,635)
* <i>acquisition of subsidiaries</i>		-	-	-	-	-	-	-	-	(2,896)
* <i>distribution of dividends</i>		-	-	-	-	-	-	(278)	(278)	(2,558)
* <i>increase in participation in subsidiaries</i>		-	-	-	-	-	-	(341)	(341)	(925)
* <i>decrease in participation in subsidiaries</i>		-	-	-	-	-	-	46	46	744
								-	-	790
Total comprehensive income for the year		-	-	-	2,501	289	(1,028)	38,404	40,166	2,401
Transfer to retained earnings		-	-	-	(106)	-	-	106	-	-
Balance at 31 December 2011	25	132,000	(11,463)	21,855	26,662	(65)	(3,455)	154,465	319,999	45,813
Changes in owners equity for 2012										
Effect of treasury shares acquisition		-	(33)	-	-	-	-	(18)	(51)	-
Distribution of profit for:										
* <i>reserves</i>		-	-	-	-	-	-	-	-	-
* <i>dividends</i>		-	-	-	-	-	-	-	-	-
Effects assumed by non-controlling interest on:		-	-	-	-	-	-	(6)	(6)	(646)
* <i>acquisition of subsidiaries</i>		-	-	-	-	-	-	-	-	-
* <i>distribution of dividends</i>		-	-	-	-	-	-	-	-	(624)
* <i>increase in participation in subsidiaries</i>		-	-	-	-	-	-	(6)	(6)	(22)
* <i>decrease in participation in subsidiaries</i>		-	-	-	-	-	-	-	-	-
Total comprehensive income for the year		-	-	-			(104)	11,333	11,229	1,355
Transfer to retained earnings		-	-	-				-	-	-
Balance at 31 March 2012	25	132,000	(11,496)	21,855	26,662	(65)	(3,559)	165,774	331,171	46,522

The accompanying notes on pages 5 to 96 form an integral part of the consolidated interim financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant (preparer):

Yordanka Petkova